{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"NewAmsterdam Pharma Company N.V."},"Symbol":{"label":"Symbol","value":"NAMS"},"Address":{"label":"Address","value":"1411, Netherlands"},"Phone":{"label":"Phone","value":"31 35 206 2971"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands."},"CompanyUrl":{"label":"Company Url","value":"https://www.newamsterdampharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bob Rambo","title":"Executive VP-Marketing & Medical Affairs"},{"name":"Douglas F. Kling","title":"Chief Operating Officer"},{"name":"John Jacob Pieter Kastelein","title":"Chief Scientific Officer & Non-Executive Director"},{"name":"Michael H. Davidson","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}